(Q26852171)

main subject

arterial hypertension

1 reference

based on heuristic

inferred from title

cardiovascular disease

1 reference

1 reference

Steven G. Chrysant

1

1 reference

George S. Chrysant

series ordinal

2

1 reference

language of work or name

1 reference

September 2012

1 reference

Journal of Clinical Hypertension

published in

1 reference

volume

14

1 reference

issue

9

1 reference

page(s)

644-9

1 reference

Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5).

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Cardiovascular data on sildenafil citrate: introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Cardiac uses of phosphodiesterase-5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Hypertension, antihypertensive therapy, and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Effects of antihypertensive therapy on sexual activity in hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Cardiovascular effects of tadalafil in patients on common antihypertensive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Effect of sildenafil on cardiac performance in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X

inferred from DOI database lookup

7 January 2021

based on heuristic

Hemodynamic effects of sildenafil in men with severe coronary artery disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2012.00669.X